H.C. Wainwright’s $20 target on VIR

VIR Vir Biotechnology Inc

$10.5 → $20 (+90%) by Sep 2027

Buy · reiterates · said Sep 28, 2026 · 12-month default horizon

Open: judged on the close on Sep 28, 2027

The article this target came from

Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data

Investing.com · Sep 28, 2026

H.C. Wainwright reiterated its Buy rating on Vir Biotechnology, maintaining a price target of $20.00

H.C. Wainwright’s track record → Vir Biotechnology Inc →

A fact about what H.C. Wainwright published, as reported by Investing.com, not a recommendation from Dalsna Finance; H.C. Wainwright is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.